CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development		$ 75,532	$ 243,002
General and administrative		1,643,163	1,528,613
Total operating expenses		1,718,695	1,771,615
Loss before other income (expense)		(1,718,695)	(1,771,615)
Interest income, net		9,162	56,325
Loss from continuing operations		(1,709,533)	(1,715,290)
Net loss		$ (1,709,533)	$ (1,715,290)
Loss per common share, basic ( in dollar per share)	[1]	$ (1.03)	$ (3.27)
Loss per common share, diluted ( in dollar per share)	[1]	$ (1.03)	$ (3.27)
Weighted average number of shares outstanding, basic (in shares)	[1]	1,663,922	524,326
Weighted average number of shares outstanding, diluted (in shares)	[1]	1,663,922	524,326

[1] Share and per share amounts have been restated to reflect the 1-for-8 reverse stock split effected in June 14, 2024 on retroactive basis for all periods presented.